Scribe signs another big pharma deal
Lilly is the latest group, after Biogen and Sanofi, to collaborate on Scribe’s novel approach to Crispr editing.
Orbital shows 2023’s venture funding scene is far from stratospheric
The group’s $270m series A, big for 2023, is not that impressive compared with other years.
Iteos – and GSK – keep the faith
With Tigit out of favour Belgium’s Iteos reckons it could have the best possible PD-(L)1 combo, but does GSK share its optimism?
Arrowhead delivers in the lung
Early clinical data with an inhaled RNA interference candidate look promising, but there is still much to prove.
Point looks to turn the tables on Novartis
Conventional wisdom says manufacturing takes second place to clinical development, but Point turned that on its head, and now a big catalyst approaches.
Checking out Checkpoint
Checkpoint Therapeutics’ cosibelimab could become the ninth PD-(L)1 drug to reach the US market, but who will be around to launch it?
Sofinnova goes digital
The promise of fast timelines and early revenues lure a new investor into digital medicine.
Zealand seeks deals in obesity and beyond
With Boehringer locked in, the Danish biotech wants more partners for monotherapies, combos and more.
Novo sows the seeds for a new heart failure approach
The company reckons it can succeed where other cell therapies have failed, but proof is a long way off.